Clinical Decision Support for Chronic Kidney Disease in Primary Care
JAMA Network Open · 08.05.2026 · 9 (5) · e2611112
DOI: 10.1001/jamanetworkopen.2026.11112 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 08.05.2026. Verfasst von Xizi Zheng und 14 weiteren Autor:innen. Beteiligte Einrichtung: Renal Division, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease, Ministry of Health of …. Hauptthemen laut MEDLINE: Primary Health Care, Renal Insufficiency, Chronic, Decision Support Systems, Clinical. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Optimal clinical decision support system (CDSS) implementation for chronic kidney disease (CKD) management in Chinese primary care remains undefined despite the high disease burden.
Objective
To examine whether a CDSS for CKD could improve physician behavior and patient outcomes in primary care. Design, Setting, and Participants This cluster randomized clinical trial is being conducted in Chinese primary care centers. The trial spans a 3-year period (January 1, 2023, to December 31, 2026) and is divided into 2 phases; this phase 1 analysis includes data from the initial 6-month follow-up (June 10 to December 10, 2023). Centers were stratified by size and randomized 1:1 to intervention or control. Participants are adults (aged ≥18 years) with CKD who had 2 visits or more during the 1-year screening period, all enrolled before randomization.
Interventions
Both groups received government-supported, nephrologist-delivered training on CKD management. The intervention group was additionally equipped with a CDSS embedded into the electronic health record. Main Outcomes and Measures The primary outcome was a 36-month composite of kidney-related and cardiovascular hospitalizations (phase 2). This phase 1 analysis evaluated 6-month process measures (ie, CKD diagnosis and renin-angiotensin-aldosterone system inhibitor or sodium-dependent glucose transporter 2 inhibitor use) and clinical outcomes (ie, blood pressure, glycated hemoglobin, and low-density lipoprotein cholesterol control).
Results
A total of 3390 patients (mean [SD] age, 72.0 [10.2] years; 1881 [55.5%] female) from 30 primary care centers were included (1912 in the intervention group and 1478 in the control group). Follow-up at 6 months was completed by 3055 patients (90.1%; 1743 [91.2%] in the intervention group and 1312 [88.8%] in the control group). CKD diagnosis rates increased by 21.4 (95% CI, 18.6-24.3) percentage points in the intervention group and by 27.9 (95% CI, 24.4-31.3) percentage points in the control group, with a nonsignificant between-group difference (adjusted odds ratio [AOR], 0.91; 95% CI, 0.72-1.14). Renin-angiotensin-aldosterone system inhibitor use (AOR, 0.96; 95% CI, 0.78-1.19), sodium-dependent glucose transporter 2 inhibitor use (AOR, 1.02; 95% CI, 0.78-1.32), and low-density lipoprotein cholesterol control (AOR, 1.10; 95% CI, 0.83-1.46) showed parallel improvements with no between-group differences. Blood pressure (AOR, 0.88; 95% CI, 0.71-1.09) and glycated hemoglobin (AOR, 1.22; 95% CI, 0.74-2.01) control showed no improvement. Conclusions and Relevance In this cluster randomized trial of a CDSS for CKD in primary care, both the intervention and control groups demonstrated comparable improvements in 6-month outcomes, with no independent effect of the CDSS detected. Trial Registration Chinese Clinical Trial Registry Identifier: ChiCTR2300070555
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Renal Division, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.
- Beijing Key Laboratory of Precision Medicine and New-drug/Equipment Development for Severe Kidney Disease, Beijing, China.
- Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China.
- Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.
- Division of Sleep Medicine, Peking University People's Hospital, Beijing, China.
- Office of Discipline and Talent, Peking University First Hospital, Beijing, China.
Zitieren
APA
Zheng, X., Hui, M., Yang, H., Yang, Z., Tang, L., Zhao, Y., Xu, L., Zhou, Q., Wang, J., Li, M., Zhu, S., Gao, F., Li, J., Lv, J., & Yang, L. (2026). Clinical Decision Support for Chronic Kidney Disease in Primary Care. JAMA Network Open, 9(5), e2611112. https://doi.org/10.1001/jamanetworkopen.2026.11112
Vancouver
Zheng X, Hui M, Yang H, Yang Z, Tang L, Zhao Y, et al. Clinical Decision Support for Chronic Kidney Disease in Primary Care. JAMA Network Open. 2026;9(5):e2611112. doi:10.1001/jamanetworkopen.2026.11112
BibTeX
@article{Zheng2026,
author = {Zheng, Xizi and Hui, Miao and Yang, Hongyu and Yang, Zhao and Tang, Linger and Zhao, Youlu and Xu, Lingyi and Zhou, Qingqing and Wang, Jingwei and Li, Mengrui and Zhu, Shuhong and Gao, Fengjuan and Li, Jing and Lv, Jicheng and Yang, Li},
title = {Clinical Decision Support for Chronic Kidney Disease in Primary Care},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {5},
pages = {e2611112},
doi = {10.1001/jamanetworkopen.2026.11112}
}
EUVIMED